Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy

Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vaccination. As part of the safety lead-in portion of a phase 2 c...

Descrición completa

Detalles Bibliográficos

Principais autores:	Flavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, Jing Li, Minh Ly, Katelyn Faircloth, Jada Mack-Onyeike, Corinna La Rosa, Sandra Thomas, Qiao Zhou, Jennifer Drake, Cynthia Slape, Paolo Fernando, Wasima Rida, Teodora Kaltcheva, Alba Grifoni, Alessandro Sette, Angela Patterson, Shannon Dempsey, Brian Ball, Haris Ali, Amandeep Salhotra, Anthony Stein, Nitya Nathwani, Michael Rosenzweig, Liana Nikolaenko, Monzr M. Al Malki, Jana Dickter, Deepa D. Nanayakkara, Alfredo Puing, Stephen J. Forman, Randy A. Taplitz, John A. Zaia, Ryotaro Nakamura, Felix Wussow, Don J. Diamond, Sanjeet S. Dadwal
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-09-01
Series:	Vaccines
Assuntos:	SARS-CoV-2 modified vaccinia Ankara (MVA) spike nucleocapsid hematopoietic cell transplantation (HCT) immunosuppression
Acceso en liña:	https://www.mdpi.com/2076-393X/11/9/1492
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!